Topiramate Capsule, Extended Release
Product Images NDC 69680-180

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Topiramate (NDC 69680-180). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Vitruvias Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (100mg)

Label for Topiramate extended-release capsules, 100 mg strength, manufactured by Xiamen LP Pharmaceutical Co., Ltd. and distributed by Vitruvias Therapeutics, Inc. The label indicates a 30-capsule package for once-daily dosing, includes a barcode, and storage instructions to keep at 20-25°C, child-resistant packaging, and dispensing guidance for pharmacists.*

FDA Label Image

Image Description (150mg)

Label for Topiramate Extended-Release Capsules 150 mg by Vitruvias Therapeutics, Inc. The label states 30 capsules per container for once-daily oral dosing. It includes storage instructions, manufacturing information by Xiamen LP Pharmaceutical Co., Ltd., and a barcode with additional coding details.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 200 mg by Vitruvias Therapeutics, Inc. The label shows the product name, strength, dosage form, and highlights once-daily dosing. It includes manufacturer information (Xiamen LP Pharmaceutical Co., Ltd.) and distributor details, along with storage instructions and a 30-capsule count. The label also contains barcode and serialized product identifiers.*

FDA Label Image

Principal Display Panel (25 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 25 mg, a human prescription drug by Vitruvias Therapeutics, Inc. The label states once-daily dosing and contains 30 capsules. It includes manufacturer information (Xiamen LP Pharmaceutical Co., Ltd.) and distribution details. The packaging features a barcode and a QR code with product identifiers and instructions to dispense a medication guide with each patient.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Label for Topiramate Extended-Release Capsules 50 mg, containing 30 capsules per bottle. This prescription medication is labeled for once-daily dosing. The label identifies Vitruvias Therapeutics, Inc. as the distributor and Xiamen LP Pharmaceutical Co., Ltd. in China as the manufacturer. Storage instructions specify keeping the package child-resistant and at controlled room temperature 20-25°C (68-77°F).*

FDA Label Image

Figure 1 (Figure 1)

A Kaplan-Meier survival curve graph showing cumulative rates for time to first seizure over 500 days. It compares two Topiramate extended-release dosage groups: 50 mg/day (solid line) and 400 mg/day (dashed line), with a p-value of 0.0002 indicating statistical comparison. The x-axis represents time in days, and the y-axis represents cumulative seizure rates.*

FDA Label Image

Figure 2 (Figure 2)

A bar chart comparing the proportion of patients (%) achieving various ranges of seizure frequency reduction from baseline (%) between placebo and Topiramate 200 mg/day groups. The horizontal axis shows seizure reduction categories from worse to 75-100%, and the vertical axis shows the proportion of patients. Placebo bars are white, and Topiramate bars are black.*

FDA Label Image

Figure 3 (Figure 3)

A bar graph illustrating the change from baseline to double-blind phase in average monthly migraine period rate (+SE) for Topiramate dosages of 50 mg/day, 100 mg/day, and 200 mg/day compared to placebo. Data from two studies, Study 11 and Study 12, show greater reductions in migraine rates with higher doses, with statistical significance indicated for 100 mg/day and 200 mg/day doses.*

FDA Label Image

Chemical Structure (Topiramate01)

Chemical structure of Topiramate showing its molecular arrangement including multiple oxygen atoms, an SO2NH2 group, and methyl groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.